Market Cap 54.43M
Revenue (ttm) 0.00
Net Income (ttm) -7.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 49,000
Avg Vol 101,988
Day's Range N/A - N/A
Shares Out 9.63M
Stochastic %K 41%
Beta 1.09
Analysts Strong Sell
Price Target $16.33

Company Profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic aller...

Industry: Biotechnology
Sector: Healthcare
Phone: 289 800 9600
Address:
100 Spy Court, Markham, Canada
joel12365
joel12365 Aug. 18 at 3:05 PM
$EDSA hey guys check out $INTS Your welcome
1 · Reply
Zephix
Zephix Aug. 18 at 2:54 PM
$EDSA Nice
0 · Reply
Treb3k
Treb3k Aug. 18 at 2:39 PM
$EDSA everyone is in a waiting game
0 · Reply
AllmightyDollah
AllmightyDollah Aug. 17 at 7:53 PM
$EDSA nice collapse.
0 · Reply
Treb3k
Treb3k Aug. 17 at 4:32 PM
$EDSA where dem bots at
0 · Reply
EireTrader
EireTrader Aug. 17 at 8:37 AM
$EDSA .... Institutional Ownership up to 40% Par has 20% Probably another 20% in strong hands So the float is about 2M Shares
0 · Reply
Treb3k
Treb3k Aug. 16 at 3:11 AM
$EDSA how are they going to fund the EB06 trials
0 · Reply
Boywithathorn
Boywithathorn Aug. 15 at 12:15 AM
$EDSA $EDSA ABCL. My favorite Canadian biotech. Almost 4 BILLION market cap now. Looking at $12 soon. Was $4 just a month or so ago. Directors buying shares at highs. Just take a look at fillings. Unlike scam artist Pardeep Kumar Nijhawan of Edesa who shorts his own company from $20 to $4 and does a shit $3,5 million offering that only paid the paychecks of his DEI shitfest employee the last 2 months. A useless fack making sense offering that only got him and shitfack Stonepipe vulture fund cheap shares. While us investors who finally thought we saw the light and are treated correct believing in the tlr4 platform not these Canadian Facks are still stuck in this shitehole 80 cent pre split. An absolute chump Pos human is Pardeep. Stock should of been $30 plus years ago. What is there to like about Pardeep? He gets terrible doctor reviews and scams shareholders! What a guy!
0 · Reply
AllmightyDollah
AllmightyDollah Aug. 14 at 8:02 PM
$EDSA nice red close with the Kumar Nijhawan scam.
0 · Reply
JoeDomiano
JoeDomiano Aug. 14 at 2:39 PM
1 · Reply
Latest News on EDSA
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

Aug 13, 2026, 4:15 PM EDT - 5 days ago

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results


Edesa Biotech files to sell 729,241 common shares for holders

2026-07-02T21:05:18.000Z - 6 weeks ago

Edesa Biotech files to sell 729,241 common shares for holders


Edesa Biotech reinstated with a Buy at Brookline

2026-06-29T19:50:30.000Z - 7 weeks ago

Edesa Biotech reinstated with a Buy at Brookline


Edesa Biotech announces $3.5M private placement

2026-06-11T13:27:38.000Z - 2 months ago

Edesa Biotech announces $3.5M private placement


Edesa Biotech Inc trading resumes

2026-05-19T13:40:50.000Z - 3 months ago

Edesa Biotech Inc trading resumes


Edesa Biotech Inc trading halted, volatility trading pause

2026-05-19T13:35:48.000Z - 3 months ago

Edesa Biotech Inc trading halted, volatility trading pause


Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

May 14, 2026, 4:30 PM EDT - 3 months ago

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results


Edesa Biotech Inc trading halted, volatility trading pause

2026-04-28T14:26:55.000Z - 4 months ago

Edesa Biotech Inc trading halted, volatility trading pause


Edesa Biotech Inc trading resumes

2026-04-28T14:20:13.000Z - 4 months ago

Edesa Biotech Inc trading resumes


Edesa Biotech provides update on EB06 clinical study

2026-03-26T13:37:21.000Z - 5 months ago

Edesa Biotech provides update on EB06 clinical study


Edesa Biotech reports Q1 EPS (28c), consensus (45c)

2026-02-13T21:25:18.000Z - 6 months ago

Edesa Biotech reports Q1 EPS (28c), consensus (45c)


Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Feb 13, 2026, 4:20 PM EST - 6 months ago

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results


Edesa Biotech Reports Fiscal Year 2025 Results

Dec 12, 2025, 4:20 PM EST - 8 months ago

Edesa Biotech Reports Fiscal Year 2025 Results


Edesa Biotech Announces Upcoming Conference Schedule

Oct 31, 2025, 4:30 PM EDT - 10 months ago

Edesa Biotech Announces Upcoming Conference Schedule


Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

Aug 8, 2025, 4:35 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results


Edesa Biotech files $150M mixed securities shelf

2025-07-25T20:50:18.000Z - 1 year ago

Edesa Biotech files $150M mixed securities shelf


Edesa Biotech assumed with a Buy at H.C. Wainwright

2025-06-27T14:35:08.000Z - 1 year ago

Edesa Biotech assumed with a Buy at H.C. Wainwright


Edesa Biotech initiated with a Buy at Lucid Capital

2025-05-23T10:55:53.000Z - 1 year ago

Edesa Biotech initiated with a Buy at Lucid Capital


Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

May 14, 2025, 4:15 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results


Edesa Biotech Announces Chief Financial Officer Transition

Apr 4, 2025, 4:15 PM EDT - 1 year ago

Edesa Biotech Announces Chief Financial Officer Transition


Edesa Biotech files to sell 7.81M common shares for holders

2025-03-04T21:36:26.000Z - 1 year ago

Edesa Biotech files to sell 7.81M common shares for holders


Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Feb 14, 2025, 4:15 PM EST - 1 year ago

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results


Edesa Biotech Reports Fiscal Year 2024 Results

Dec 13, 2024, 4:30 PM EST - 1 year ago

Edesa Biotech Reports Fiscal Year 2024 Results


Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Aug 9, 2024, 4:20 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results


Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

May 10, 2024, 4:15 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results


Edesa Biotech to Participate in Upcoming Investor Conferences

Apr 2, 2024, 9:00 AM EDT - 2 years ago

Edesa Biotech to Participate in Upcoming Investor Conferences


Edesa Biotech to Participate in Upcoming Dermatology Meetings

Mar 4, 2024, 4:30 PM EST - 2 years ago

Edesa Biotech to Participate in Upcoming Dermatology Meetings


Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Feb 9, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results


Edesa Biotech Reports Fiscal Year 2023 Results

Dec 15, 2023, 4:10 PM EST - 2 years ago

Edesa Biotech Reports Fiscal Year 2023 Results


Edesa Biotech to Present at Dermatology Drug Development Summit

Oct 26, 2023, 4:05 PM EDT - 3 years ago

Edesa Biotech to Present at Dermatology Drug Development Summit


Edesa Biotech Announces One-for-Seven Reverse Share Split

Oct 10, 2023, 9:00 AM EDT - 3 years ago

Edesa Biotech Announces One-for-Seven Reverse Share Split


Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Aug 9, 2023, 4:15 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal Third Quarter 2023 Results


Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Jun 27, 2023, 8:15 AM EDT - 3 years ago

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role


Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

Jun 15, 2023, 8:00 AM EDT - 3 years ago

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name


Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

May 11, 2023, 4:30 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results


Edesa Biotech to Participate in Swiss Biotech Day

Apr 20, 2023, 8:30 AM EDT - 3 years ago

Edesa Biotech to Participate in Swiss Biotech Day


Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Feb 10, 2023, 9:00 AM EST - 3 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results


joel12365
joel12365 Aug. 18 at 3:05 PM
$EDSA hey guys check out $INTS Your welcome
1 · Reply
Zephix
Zephix Aug. 18 at 2:54 PM
$EDSA Nice
0 · Reply
Treb3k
Treb3k Aug. 18 at 2:39 PM
$EDSA everyone is in a waiting game
0 · Reply
AllmightyDollah
AllmightyDollah Aug. 17 at 7:53 PM
$EDSA nice collapse.
0 · Reply
Treb3k
Treb3k Aug. 17 at 4:32 PM
$EDSA where dem bots at
0 · Reply
EireTrader
EireTrader Aug. 17 at 8:37 AM
$EDSA .... Institutional Ownership up to 40% Par has 20% Probably another 20% in strong hands So the float is about 2M Shares
0 · Reply
Treb3k
Treb3k Aug. 16 at 3:11 AM
$EDSA how are they going to fund the EB06 trials
0 · Reply
Boywithathorn
Boywithathorn Aug. 15 at 12:15 AM
$EDSA $EDSA ABCL. My favorite Canadian biotech. Almost 4 BILLION market cap now. Looking at $12 soon. Was $4 just a month or so ago. Directors buying shares at highs. Just take a look at fillings. Unlike scam artist Pardeep Kumar Nijhawan of Edesa who shorts his own company from $20 to $4 and does a shit $3,5 million offering that only paid the paychecks of his DEI shitfest employee the last 2 months. A useless fack making sense offering that only got him and shitfack Stonepipe vulture fund cheap shares. While us investors who finally thought we saw the light and are treated correct believing in the tlr4 platform not these Canadian Facks are still stuck in this shitehole 80 cent pre split. An absolute chump Pos human is Pardeep. Stock should of been $30 plus years ago. What is there to like about Pardeep? He gets terrible doctor reviews and scams shareholders! What a guy!
0 · Reply
AllmightyDollah
AllmightyDollah Aug. 14 at 8:02 PM
$EDSA nice red close with the Kumar Nijhawan scam.
0 · Reply
JoeDomiano
JoeDomiano Aug. 14 at 2:39 PM
1 · Reply
EdV3
EdV3 Aug. 14 at 1:21 AM
$EDSA until theres an approved ind on eb06 its all smoke and mirrors coming up a year now on pari readout seems like an awful long time for a "blockbuster" drug to sit around w/o a partner or getting snapped up Just breathe data could unlock that....but when....
1 · Reply
Boywithathorn
Boywithathorn Aug. 14 at 12:20 AM
$EDSA How is it allowed for a Nasdaq traded company to tell investors for 7 years about fake partnerships and never an on time trial? How can they expect to dillute shareholders for 3 years without anything going on and just them receiving paychecks? And the fact of no dilution at the highest prices when they had every chance with ATM just shows they are literally scam artists. I will contact the SEC again on this shitfest Canadian DEI joke.
0 · Reply
Treb3k
Treb3k Aug. 13 at 10:41 PM
$EDSA they could have sold a couple hundred thousand shares into millions of shares of volume above $15. Did they believe it was undervalued at that price?
0 · Reply
Treb3k
Treb3k Aug. 13 at 10:37 PM
$EDSA AND ITS INSANE THEY DIDNT USE THE ATM! ITS THE CRAZIEST SIGNAL OF ALL
0 · Reply
Treb3k
Treb3k Aug. 13 at 10:37 PM
$EDSA pt. 4 Bottom line: Fundamentally encouraging quarter for the pipeline. EB05 is being prepared for something bigger — manufacturing scale-up + late-stage planning + partner discussions — but Edesa doesn’t currently have the balance sheet to fund that “something bigger” itself. IMO the whole $EDSA setup increasingly comes down to: Does BARDA/PreventARDS, HERA/Canada, or a pharma partner fund the next stage of EB05? If yes → today’s CMC/partnering breadcrumbs could look very important in hindsight. If no → financing/dilution becomes the story.
0 · Reply
Treb3k
Treb3k Aug. 13 at 10:36 PM
$EDSA pt. 3 🔴 No BARDA PreventARDS award yet. No hidden RRPV announcement in the 10-Q. 🔴 Cash is the problem: $10.3M at quarter end after the $3.5M raise. Company still says additional financing is required. Rough runway looks ~6–10 months depending on burn/working capital. 🔴 Shares outstanding ~8.4% higher since May; more dilution likely absent non-dilutive funding/partner.
0 · Reply
Treb3k
Treb3k Aug. 13 at 10:35 PM
$EDSA pt 2 🟡 JUST BREATHE still progressing, but no enrollment/readout update. 🟡 Canadian reimbursement increased $66K$107K QoQ, but still small.
0 · Reply
Treb3k
Treb3k Aug. 13 at 10:34 PM
$EDSA courtesy of Chat GPT $EDSA Q3 quick take: 🧵 🟢 EB05 activity accelerating — spend +75% QoQ ($193K$338K) 🟢 Biggest breadcrumb: Edesa says it has initiated paridiprubart manufacturing readiness, including process development + scale-up planning for future drug production. 🟢 Management now explicitly mentions potential partners, major-market regulatory pathways + advancing EB05 through late-stage development. 🟢 New ARDS+AKI data now incorporated into the formal program narrative. 🟢 EB06 moving: ~$3.0M quarterly spend, FDA IND/CMC work underway, site activation started and Canadian enrollment expected soon
0 · Reply
AllmightyDollah
AllmightyDollah Aug. 13 at 9:32 PM
$EDSA So this sums up Edesa and scam artist Pardeep Kumar Nijhawan. Short your own stock from $20 to $4 in a month. Do a very small offering at $4 with you buying half with your buddies buying other half. Lie to investors that this is for the start of the Eb06 trial. Months went by and trial never started. We get earnings today and same old bs that trial will start soon. (Saying that 3 years). Also same old bs that on eb05 we are talking with partners and regulators. (Saying that 6 years). The fact that this company did not raise any capital on the stock jump to $20 tells you the story here. They were happy to use ATM at $1/6 months ago and do offerings (selling 30% of company to Velan) at $2 and $4 over the last 2 years. But didn’t use the ATM at $20. And didn’t try to do any offering near those prices. Now we are sitting here with 6 million dollars in the bank saying we still plan on staring a trial soon even though we haven’t run a facking trial in 3 years. Scam!
0 · Reply
AllmightyDollah
AllmightyDollah Aug. 13 at 8:38 PM
$EDSA the scam is continuing lies. Still bs about regulatory pathways for eb05, partners and then to top It off Eb06 is still planned to start soon. When can we put this scammer in jail?
0 · Reply
mapleleafdave
mapleleafdave Aug. 13 at 5:58 PM
0 · Reply
Treb3k
Treb3k Aug. 13 at 2:25 PM
0 · Reply